Step 1 topics → Psychiatry → Opioid Use — Intoxication, Withdrawal, Maintenance

Opioid Use — Intoxication, Withdrawal, Maintenance

USMLE Step 1 trap: Overestimates the lethality of opioid withdrawal relative to alcohol/benzo withdrawal. Opioid withdrawal is extremely uncomfortable (flu-like symptoms, piloerection, diarrhea, mydriasis) but is not directly life-threatening in otherwise healthy adults, unlike alcohol or benzo withdrawal.

Opioid use disorder — covering intoxication, overdose management, withdrawal, and maintenance therapy — is one of the highest-yield psychiatry topics on USMLE Step 1. The exam hits this from multiple angles: pure recall of the intoxication triad, clinical application of naloxone dosing, comparison questions that pit opioid withdrawal against alcohol/benzo withdrawal, and pharmacology of methadone versus buprenorphine versus naltrexone. You need to know not just the facts but when and why each applies.

What makes this topic tricky is that students conflate severity across substance withdrawal syndromes and mix up the prescribing rules for maintenance agents. Opioid withdrawal feels dramatic clinically — piloerection, vomiting, diarrhea, mydriasis, severe anxiety — but it is not directly lethal in a healthy adult. Alcohol and benzo withdrawal can kill. That distinction shows up in USMLE Step 1 vignettes where you're asked to rank urgency or identify the most dangerous withdrawal scenario. Getting that wrong means confusing uncomfortable with dangerous.

The other common trap is treating methadone and buprenorphine as interchangeable office prescriptions. They're not — methadone for OUD requires a federally certified opioid treatment program, while buprenorphine (Suboxone) can be prescribed from an outpatient office by a waivered provider. The exam also loves naloxone pharmacokinetics: students know to give it for overdose but forget that one dose won't cover a methadone overdose because naloxone's half-life is much shorter, creating re-narcotization risk.

From real student decks
84%have cards covering this topic
70%have mature cards
1median lapses in 14 days

Common misconceptions

Common mistake
Wrong: Opioid withdrawal is life-threatening like alcohol or benzodiazepine withdrawal.
Right: Opioid withdrawal is extremely uncomfortable (flu-like symptoms, piloerection, diarrhea, mydriasis) but is not directly life-threatening in otherwise healthy adults, unlike alcohol or benzo withdrawal.
Opioid withdrawal is miserable — think severe flu with diarrhea, vomiting, piloerection, mydriasis, and intense craving — but it does not cause the autonomic instability that kills people in alcohol or benzo withdrawal (seizures, delirium tremens). The danger in opioid withdrawal is dehydration and relapse, not direct cardiovascular or neurological collapse. On USMLE Step 1 questions asking which withdrawal requires ICU-level monitoring or is most immediately dangerous, the answer is alcohol or benzos, not opioids.
Common mistake
Wrong: A single dose of naloxone is sufficient for overdose on long-acting opioids like methadone.
Right: Naloxone has a shorter half-life than long-acting opioids such as methadone, so repeated dosing or a continuous infusion is required to prevent re-narcotization.
Naloxone works by competitively blocking opioid receptors, but its half-life is only 30–90 minutes — far shorter than methadone, which lasts 24–36 hours. If you give one dose of naloxone to a methadone-overdosed patient, they may wake up initially, but as the naloxone wears off, the methadone still on board re-sedates them (re-narcotization). The fix is repeated naloxone boluses or a continuous infusion, and close observation. Never assume the patient is 'fixed' after a single naloxone dose in a long-acting opioid overdose.
Common mistake
Wrong: Methadone and buprenorphine can both be prescribed from any outpatient office for opioid use disorder.
Right: Methadone for OUD must be dispensed through federally certified opioid treatment programs (OTPs), while buprenorphine can be prescribed in office-based settings by waivered providers.
This is a regulatory distinction the exam tests directly. Methadone for OUD (not pain) must be dispensed daily through a federally certified Opioid Treatment Program — patients physically go to the clinic. Buprenorphine (often as Suboxone, combined with naloxone) can be prescribed in a regular outpatient office by providers who have obtained a DEA waiver. Naltrexone has no special setting requirements. Mixing these up on a vignette about treatment planning will cost you points.
Common mistake
Gap: Incomplete recall of the opioid intoxication triad, particularly the specificity of miosis
The classic opioid intoxication triad is miosis, respiratory depression, and altered consciousness (CNS depression); miosis is the most specific finding and persists even with tolerance.
The triad is miosis + respiratory depression + CNS depression (altered consciousness). Students often forget one component or list the wrong third element. Miosis is the key discriminating sign — pupils are pinpoint even in a comatose patient, and importantly, miosis persists with chronic use despite tolerance developing to euphoria and analgesia. If a vignette shows a patient with pinpoint pupils and depressed breathing, that's opioid toxicity until proven otherwise, and naloxone is your intervention.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Recognize the classic opioid intoxication triad — miosis, respiratory depression, and CNS depression (altered consciousness) — and understand that miosis is the most specific finding, persisting even in tolerant users.
  2. Apply naloxone correctly in an overdose scenario, including the need for repeated dosing or continuous infusion when the overdose involves a long-acting opioid like methadone, due to naloxone's shorter half-life.
  3. Distinguish the opioid withdrawal syndrome (flu-like: piloerection, diarrhea, mydriasis, yawning, lacrimation) from alcohol and benzodiazepine withdrawal, specifically recognizing that opioid withdrawal is not directly life-threatening while the others can be.
  4. Differentiate the three maintenance pharmacotherapy options — methadone (full agonist, OTP-only), buprenorphine (partial agonist, office-based), and naltrexone (antagonist, no physical dependence required) — including their mechanisms, clinical settings, and appropriate patient selection.

Can you avoid these mistakes?

A 32-year-old is brought to the ED unresponsive with pinpoint pupils and a respiratory rate of 6/min. He receives IV naloxone and wakes up. Twenty minutes later he becomes unresponsive again. What is the most likely explanation, and what is the next step in management?
You are presented with two patients in withdrawal: one from heroin, one from alcohol. Which patient requires closer monitoring for life-threatening complications, and what specific complications differentiate the two syndromes?
A patient with opioid use disorder wants to start maintenance therapy but lives in a rural area and cannot travel daily to a clinic. Which agent is most appropriate, and why can't you use methadone in this setting?
A patient on chronic high-dose opioids for cancer pain presents with the classic intoxication triad. Which component of the triad is most specific for opioid toxicity and would still be expected even if the patient had developed tolerance to other opioid effects?

Related topics

Major Depressive Disorder (MDD) Persistent Depressive Disorder (Dysthymia) Bipolar I Disorder Bipolar II Disorder

See how your Anki deck covers this topic.

Upload your deck for a free audit →